4D Molecular Therapeutics, Inc.

NASDAQ:FDMT

16.82 (USD) • At close September 18, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) USD.

2024 Q22024 Q12023 Q42023 Q32023 Q22023 Q12022 Q42022 Q32022 Q22022 Q12021 Q42021 Q32021 Q22021 Q12020 Q42020 Q32020 Q22020 Q12019 Q42019 Q32019 Q22019 Q12018 Q42018 Q32018 Q22018 Q1
Revenue 0.0050.028-0.01920.2040.2390.2981.2470.50.1621.2190.0921.36614.582-0.9777.4213.6333.5352.030.542.2082.2084.5314.5312.5352.535
Cost of Revenue 1.6241.5944.2361.3961.4281.4121.3880.8790.8310.7821.88715.8415.22312.76912.60511.55515.7213.15812.3599.3748.4938.4935.0775.0774.1044.104
Gross Profit -1.619-1.566-4.25518.808-1.189-1.114-0.141-0.379-0.6690.437-1.795-14.474-0.643-10.769-13.582-4.134-12.087-9.623-10.329-8.834-6.285-6.285-0.547-0.547-1.57-1.57
Gross Profit Ratio -323.8-55.929223.9470.931-4.975-3.738-0.113-0.758-4.130.358-19.511-10.596-0.044-5.38513.902-0.557-3.327-2.722-5.088-16.359-2.846-2.846-0.121-0.121-0.619-0.619
Reseach & Development Expenses 31.8627.8726.02825.06623.58422.41221.518.9420.42219.38117.52815.8415.22312.76912.60511.55515.7213.15812.3599.3748.4938.4935.0775.0774.1044.104
General & Administrative Expenses 10.60110.29410.6059.1128.7917.9928.4678.0558.1668.237.3288.1876.9535.5436.843.6823.0623.6545.9593.0522.4422.4421.9851.9851.0991.099
Selling & Marketing Expenses -1.624-1.594000000000000000000000000
SG&A 8.9778.710.6059.1128.7917.9928.4678.0558.1668.237.3288.1876.9535.5436.843.6823.0623.6545.9593.0522.4422.4421.9851.9851.0991.099
Other Expenses -0.045-0.01-0.011-0.1582.521.4240.0030.0090-0.046-0.007-0.0130-0.101-0.129-0.021-0.018-0.013-0.0450.007000000
Operating Expenses 40.83736.5736.63334.17832.37530.40429.96726.99528.58827.61124.85624.02722.17618.31219.44515.23718.78216.81218.31812.4262.4462.4461.9881.9881.0971.097
Operating Income -42.456-38.136-36.652-13.974-32.136-30.106-28.72-26.495-28.426-26.392-24.764-22.661-7.596-16.312-20.422-7.816-15.149-13.277-16.288-17.023-8.727-8.727-2.531-2.531-2.669-2.669
Operating Income Ratio -8,491.2-1,3621,929.053-0.692-134.46-101.027-23.031-52.99-175.469-21.651-269.174-16.589-0.521-8.15620.903-1.053-4.17-3.756-8.024-31.524-3.952-3.952-0.559-0.559-1.053-1.053
Total Other Income Expenses Net 7.5035.735-0.011-0.1582.521.4241.3410.8040.340.054-0.007-0.0130.007-0.101-0.129-0.021-0.018-0.013-0.045-5.130.4690.4690.3490.3490.0760.076
Income Before Tax -34.953-32.401-32.283-10.256-29.616-28.682-27.379-25.691-28.086-26.338-25.083-22.239-7.589-16.406-20.547-7.833-15.153-13.16-16.115-16.675-8.258-8.258-2.183-2.183-2.593-2.593
Income Before Tax Ratio -6,990.6-1,157.1791,699.105-0.508-123.916-96.248-21.956-51.382-173.37-21.606-272.641-16.28-0.521-8.20321.031-1.056-4.171-3.723-7.938-30.88-3.74-3.74-0.482-0.482-1.023-1.023
Income Tax Expense 0-06.728-3.876-1.428-1.424-0.106-1.599-0.68-0.1540.312-0.4350-0.007-0.004-0.004-0.014-0.13-0.218-0.341000000
Net Income -34.953-32.401-32.283-10.256-29.616-27.258-27.273-24.092-27.406-26.184-25.083-22.239-7.589-16.406-20.547-7.833-15.153-13.16-16.115-16.675-8.258-8.258-2.183-2.183-2.593-2.593
Net Income Ratio -6,990.6-1,157.1791,699.105-0.508-123.916-91.47-21.871-48.184-169.173-21.48-272.641-16.28-0.521-8.20321.031-1.056-4.171-3.723-7.938-30.88-3.74-3.74-0.482-0.482-1.023-1.023
EPS -0.63-0.66-0.83-0.24-0.77-0.83-0.84-0.74-0.85-0.81-0.93-0.82-0.28-0.61-0.77-0.36-1.02-0.89-1.09-1.12-1.61-1.61-0.43-0.43-0.52-0.52
EPS Diluted -0.63-0.66-0.83-0.24-0.77-0.83-0.84-0.74-0.85-0.81-0.93-0.82-0.28-0.61-0.77-0.36-1.02-0.89-1.09-1.12-1.61-1.61-0.43-0.43-0.52-0.52
EBITDA -40.832-36.542-35.139-12.578-32.136-30.106-27.332-25.616-27.595-25.61-22.877-22.279-7.226-15.931-20.051-7.447-14.79-12.933-15.97-11.606-8.524-8.524-2.353-2.353-2.498-2.498
EBITDA Ratio -8,166.4-1,305.0711,849.421-0.623-134.46-101.027-21.918-51.232-170.34-21.009-248.663-16.31-0.496-7.96620.523-1.004-4.071-3.659-7.867-21.493-3.86-3.86-0.519-0.519-0.986-0.986